8-K: Microbot Medical's LIBERTY System Achieves Milestones at Emory

Emory Healthcare successfully completed robotic peripheral endovascular procedures using Microbot Medical's LIBERTY Endovascular Robotic System for BPH and liver cancer.

Summary

• Emory Healthcare successfully utilized Microbot Medical's LIBERTY Endovascular Robotic System for minimally invasive peripheral endovascular procedures.
• The system demonstrated successful application in treating benign prostatic hyperplasia (BPH) and liver cancer.
• Emory physicians performed the world's first robotic Prostatic Artery Embolization (PAE) for BPH using the LIBERTY system.
• The team also completed the first robotic Yttrium-90 (Y-90) radioembolization mapping for liver cancer with the same hand-held robotic system.
• The LIBERTY System is the only FDA-cleared, single-use, remotely operated robotic system for peripheral endovascular procedures, designed for precision, efficiency, and safety, aiming to reduce radiation exposure and physical strain.

Sentiment

Score: 8

Explanation: StockSavvy.ai views this as a highly positive development, demonstrating significant clinical validation and expanding the potential market for the LIBERTY system, which could drive future adoption and revenue growth.

Positives

• Successful completion of robotic peripheral endovascular procedures at Emory Healthcare using the LIBERTY System.
• Demonstrated successful use for benign prostatic hyperplasia (BPH) and liver cancer, significantly expanding the system's application scope.
• Performance of the world's first robotic Prostatic Artery Embolization (PAE) for BPH with the LIBERTY System.
• Completion of the first robotic Y-90 radioembolization mapping for liver cancer using the system.
• The LIBERTY System is the only FDA-cleared, single-use, remotely operated robotic system for peripheral endovascular procedures.
• Potential to establish endovascular robotic navigation as the standard of care for PAE, mirroring the adoption of robotic-assisted prostatectomy for prostate cancer.
• Aims to improve efficiency, precision, reduce radiation exposure, and alleviate physical strain for clinicians.

Risks

• Market conditions.
• Risks inherent in the commercialization of the LIBERTY Endovascular Robotic System.
• Risks in the development of future versions of or applications for the system.
• Uncertainty in the results of regulatory pathways and regulatory approvals.
• Uncertainty resulting from political, social, and geopolitical conditions, particularly any changes in personnel or processes or procedures at the FDA.
• Announcements of tariffs on imports into the U.S.
• Disruptions resulting from new and ongoing hostilities between Israel and the Palestinians, Iran, and other neighboring countries.
• Maintenance of intellectual property rights.

Future Outlook

Microbot believes the LIBERTY system can expand patient access to high-quality care and establish endovascular robotic navigation as the standard of care for PAE in patients with enlarged prostates. The company plans for a Full Market Release at the Society of Interventional Radiology conference in April 2026, with the goal to deepen market adoption.

Management Comments

• "I'm excited to be part of the first team performing the robotic PAE with the LIBERTY system at Emory. Using the new system for PAE assists in navigating and handling challenging anatomy with precision. I believe that it represents a significant advancement in how interventional radiologists will approach prostate artery embolization." Zachary L. Bercu, MD, an interventional radiologist with Emory Healthcare.
• "The endovascular robotic procedure allows specialists to develop personalized care for liver cancer, steering precisely to the target to deliver a nuanced treatment for each patient." Zachary L. Bercu, MD, an interventional radiologist with Emory Healthcare.
• "With a sizeable patient population, we believe that LIBERTY can establish endovascular robotic navigation as the standard of care for PAE in patients with enlarged prostates, mirroring how robotic-assisted prostatectomy became the dominant surgical approach for prostate cancer." Harel Gadot, Microbot Medical Chairman, CEO & President.
• "The successful completion of LIBERTY's cases at Emory reinforces our confidence in the innovation and benefits it can bring to clinicians, patients and procedural workflow." Harel Gadot, Microbot Medical Chairman, CEO & President.

Industry Context

StockSavvy.ai notes that the successful application of robotic technology in peripheral endovascular procedures for BPH and liver cancer aligns with the broader trend of increasing adoption of minimally invasive and robotic-assisted surgeries across various medical specialties. This development positions Microbot Medical to potentially capture a significant share in the growing market for advanced surgical robotics, particularly in interventional radiology, where precision and reduced invasiveness are highly valued.

Comparison to Industry Standards

• The successful robotic PAE for BPH with the LIBERTY system is presented as the "world's first," suggesting a pioneering achievement in this specific application compared to existing manual or less advanced robotic methods.
• The company explicitly draws a parallel to how "robotic-assisted prostatectomy became the dominant surgical approach for prostate cancer," implying that LIBERTY aims to achieve a similar market dominance for PAE, setting a new standard against traditional approaches.
• The LIBERTY System is highlighted as the "only FDA-cleared, single-use, remotely operated robotic system for peripheral endovascular procedures," differentiating it from multi-use or non-remote systems from competitors like Intuitive Surgical (Da Vinci system, primarily for general surgery) or other emerging robotic platforms that may not have this specific combination of features or FDA clearance for peripheral endovascular use.

Stakeholder Impact

• Shareholders: Positive impact due to successful clinical validation, expanded market potential, and increased confidence in the company's technology, potentially leading to increased share value.
• Patients: Improved access to high-quality, minimally invasive treatments for conditions like BPH and liver cancer, with potential for greater precision, reduced radiation exposure, and improved outcomes.
• Clinicians (Interventional Radiologists): Enhanced precision and control during complex procedures, reduced physical strain, improved procedural efficiency, and a significant advancement in treatment approaches.
• Emory Healthcare: Positions Emory as a leader in adopting advanced robotic technology for endovascular procedures.

Next Steps

• Full Market Release of the LIBERTY system at the Society of Interventional Radiology conference in April 2026.
• Deepening market adoption of the LIBERTY system.

Key Dates

Recommendation

The successful completion of "world's first" robotic procedures for significant conditions like BPH and liver cancer at a reputable institution like Emory Healthcare provides strong clinical validation for Microbot Medical's LIBERTY system. This expands the system's addressable market, reinforces its competitive advantage as the only FDA-cleared single-use remotely operated system for peripheral endovascular procedures, and sets the stage for the upcoming Full Market Release. These milestones suggest significant future growth potential and market adoption, making the stock a strong buy for investors looking for exposure to innovative medical robotics.

Keywords

Microbot Medical, MBOT, LIBERTY System, Endovascular Robotic System, Robotic Surgery, Peripheral Endovascular Procedures, Benign Prostatic Hyperplasia, BPH, Prostatic Artery Embolization, PAE, Liver Cancer, Y-90 Radioembolization, FDA Cleared, Medical Device, Robotics, Healthcare Technology